Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
Fate Therapeutics will present encore Phase 1 clinical data for FT819, its off-the-shelf anti-CD19 CAR T-cell candidate, and preclinical data for its dual anti-CD19/CD38 candidate FT839 at the CCR-West 2026 meeting in Huntington Beach, CA on September 17-20. In the SLE arm of the Phase 1 trial, 16 patients were treated in Regimen A with a single FT819 dose plus fludarabine-free conditioning, and 13 had at least one month of follow-up as of the May 14, 2026 cutoff, with no dose-limiting toxicities, no Grade 3 or greater cytokine release syndrome, and no ICANS, GvHD, or IEC-HS cases reported.
Key figures
- Drug Name
- FT819
- Phase Of Trial
- Phase 1
- Gvhd cases
- 0
- Data cutoff
- May 14, 2026
- Icans cases
- 0
- Iec hs cases
- 0
- Grade3 plus crs
- 0
- Sle patients treated
- 16
- Dose limiting toxicities
- 0
- Upcr reduction all regimen a
- 1.15 g/g
- Upcr reduction ft819 plus bendamustine
- 1.8 g/g
- Patients with at least one month followup
- 13
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.